4 results about "Skin Lightening Agent" patented technology

The application belongs to the technical field of biomedical optical imaging, and more particularly relates to a biosafe skin optical clearing agent and method based on a lysine synergistic system. The biosafe skin optical clearing agent provided in the application contains lysine or a salt thereof as an active ingredient, can effectively reduce the light scattering of skin tissue, and thus realizes the optical clearing of skin, and meanwhile, the morphology of the skin tissue is well maintained during the treatment. The skin optical clearing agent has the advantages of simple active ingredient, high biosafety, remarkable skin optical clearing effect, convenient preparation, simple application operation and the like, and is suitable for the optical clearing treatment of ex vivo skin and in vivo skin.

A formula for a beauty and complexion-enhancing agent, comprising the following raw materials: 12-15 parts of Polygonum multiflorum Thunb., 9-12 parts of Angelica dahurica, 4-6 parts of Aconiti Lateralis Radix Praeparata, 6-8 parts of honey, 0.1-0.3 parts of sodium hyaluronate, and 3-4 parts of ginger juice. The advantages of the invention are as follows: the processed Aconiti Lateralis Radix Praeparata effectively reduces its toxicity, while the other ingredients are all natural components, causing minimal skin irritation, making it safe and reliable to use; by combining Polygonum multiflorum Thunb., Angelica dahurica, and Aconiti Lateralis Radix Praeparata, the formula provides multiple effects including hydrating and locking in moisture, improving skin dryness and roughness, reducing scars, alleviating acne inflammation, and decreasing pigmentation, thereby comprehensively improving skin condition.

The present invention relates to the cosmetic use of an oily extract of the solid residues of preserved flowers as a skin lightening agent. It also relates to a cosmetic composition comprising, in a physiologically acceptable medium, an oily extract of the residues of preserved flowers and hexylresorcinol; and the use of this composition.

The present disclosure relates to novel uses, compounds and topical compsitions of a compound of formula (I) comprising a 3,4-saturated 2H-pyran moiety,, for covalently binding to a substrate comprising amino groups, and in particular to skin and / or to hair; wherein the compound of formula (I) covalently binds to the substrate by the reaction of its 3,4-saturated 2H-pyran moiety with the amino groups comprised by the substrate; wherein the compound of formula (I), after having covalently bound to the substrate, is providing color to the substrate, and / or binds one or more active ingredients to the substrate; wherein, if active ingredient(s) is(are) present, the one or more active ingredients are, in particular and independently from each other, selected from a moisturizer, a pesticide, a fragrance, a pharmaceutical, a skin whitening agent, UVA- and / or UVB-absorbing moiety, a color-imparting moiety, a cosmetic hair coating agent, and a primer for attaching dyes to hair; wherein the compound of formula (I) comprises the one or more active ingredients, if present, independently from each other: a) as the active ingredient, or b) as a precursor of the active ingredient, wherein the compound of formula (I) is cleavable to release the active ingredient from the precursor after the application of the compound of formula (I) to the substrate (in the following: "the corresponding precursor thereof"); and c) wherein one of A1 and A2 represents said active ingredient or the corresponding precursor thereof; wherein L1 and L2 represent, independently from each other, a linker group or are absent; wherein each of A1 and A2 not representing one of the one or more active ingredients and precursors represents hydrogen, a C1-C30 moiety, hydroxyl, amino, or a halogen; wherein R1 represents hydrogen or a protective group hydrolysable after application of the compound of formula (I) to the substrate; wherein R2 and R3 independently from each other represent H or a C1-C30 moiety; and wherein the compound is not oleuropein aglycone, elenolic acid, or a tautomer and / or a pharmaceutically acceptable salt thereof.